These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 91166)
61. T lymphocyte tolerance and early appearance of virus-induced cell surface antigens in Moloney-murine leukemia virus neonatally injected mice. Collavo D; Zanovello P; Biasi G; Chieco-Bianchi L J Immunol; 1981 Jan; 126(1):187-93. PubMed ID: 6969741 [TBL] [Abstract][Full Text] [Related]
62. Presence of T cell-associated surface antigens on murine NK cells. Pollack SB; Tam MR; Nowinski RC; Emmons SL J Immunol; 1979 Oct; 123(4):1818-21. PubMed ID: 314475 [TBL] [Abstract][Full Text] [Related]
63. Virion and non-virion murine leukemia membrane antigens: analysis with virus-absorbed antisera. Moroni C; Robert-Guroff M; Martin D Intervirology; 1974; 3(5-6):292-304. PubMed ID: 4443190 [No Abstract] [Full Text] [Related]
64. Cell surface expression of cytotoxic T lymphocyte-defined, AKR/Gross leukemia virus-associated tumor antigens by normal AKR.H-2b splenic B cells. Green WR J Immunol; 1983 Dec; 131(6):3078-84. PubMed ID: 6605998 [TBL] [Abstract][Full Text] [Related]
65. Immunogenicity of subcellular fractions and molecular species of MuLV-induced tumors. III. Stimulation of syngeneic antitumor responses by subcellular fractions and molecular species of Moloney virus-induced tumors in CBA and A mice. Ahituv A; Naor D; Sharon R; Tarcic N; Klein BY Cancer Immunol Immunother; 1982; 14(1):16-26. PubMed ID: 6186365 [TBL] [Abstract][Full Text] [Related]
66. Characterization of a CD4(L3T4)-positive cytotoxic T cell clone that is restricted by class I major histocompatibility complex antigen on FBL-3 tumor cell. Matsubayashi Y; Zenita K; Morioka A; Iwashiro M; Masuda T; Uchino H; Fujita T; Kuribayashi K Immunobiology; 1989 Nov; 180(1):33-46. PubMed ID: 2483152 [TBL] [Abstract][Full Text] [Related]
67. Serum requirements for in vivo modulation of thymus-leukemia antigens on mouse leukemia cells and thymocytes. Stackpole CW J Natl Cancer Inst; 1979 Jun; 62(6):1529-36. PubMed ID: 312352 [TBL] [Abstract][Full Text] [Related]
68. Characterization of a cloned ultraviolet radiation (UV)-induced suppressor T cell line that is capable of inhibiting anti-UV tumor-immune responses. Roberts LK J Immunol; 1986 Mar; 136(5):1908-16. PubMed ID: 2936813 [TBL] [Abstract][Full Text] [Related]
69. Common leukemia-associated antigen of DBA/2 mouse leukemia detected by tumor rejection and complement-dependent cytotoxicity assays. Kawashima K; Takeyama H; Takahashi T; Kato Y; Watanabe E; Suzuki H; Minam S; Isobe K; Yamada K; Ito Y Gan; 1979 Dec; 70(6):769-76. PubMed ID: 94022 [TBL] [Abstract][Full Text] [Related]
70. Alloantigen-induced T-cell proliferation: Lyt phenotype of responding cells and blocking of proliferation by Lyt antisera. Nakayama E; Dippold W; Shiku H; Oettgen HF; Old LJ Proc Natl Acad Sci U S A; 1980 May; 77(5):2890-4. PubMed ID: 6967215 [TBL] [Abstract][Full Text] [Related]
71. Heterogeneity of the effector cells in the cytotoxic reaction against allogeneic lymphoma cells. Forman J; Britton S J Exp Med; 1973 Feb; 137(2):369-86. PubMed ID: 4539847 [TBL] [Abstract][Full Text] [Related]
72. Complement sensitivity of somatic hybrids of a complement-resistant murine leukemia cell line. Liang W; Cohen EP J Natl Cancer Inst; 1975 Aug; 55(2):309-17. PubMed ID: 51086 [TBL] [Abstract][Full Text] [Related]
73. Alloantisera reacting with tumor cells of inappropriate haplotype. I. Characterization of target antigens. Prat M; Rogers MJ; Appella E J Natl Cancer Inst; 1978 Aug; 61(2):527-34. PubMed ID: 79659 [No Abstract] [Full Text] [Related]
74. Therapy of murine leukemia with monoclonal antibody against a normal differentiation antigen. Badger CC; Bernstein ID J Exp Med; 1983 Mar; 157(3):828-42. PubMed ID: 6403649 [TBL] [Abstract][Full Text] [Related]
75. In vitro generation of cytotoxic lymphocytes against radiation- and radiation leukemia virus-induced tumors. III. Suppression of anti-tumor immunity in vitro by lymphocytes of mice undergoing radiation leukemia virus-induced leukemogenesis. Yefenof E; Meidav A; Kedar E J Exp Med; 1980 Dec; 152(6):1473-83. PubMed ID: 6256461 [TBL] [Abstract][Full Text] [Related]
76. Lysis of FLD-3 Friend erythroleukemia cells in vitro and in vivo: effect of 89Sr treatment and Friend virus infection. Lust JA; Bennett M; Kumar V Int J Cancer; 1984 Jan; 33(1):107-13. PubMed ID: 6582049 [TBL] [Abstract][Full Text] [Related]
77. Target cell heterogeneity in murine leukemia virus infection. III. Identification of susceptible Lyt 1+ and resistant Lyt 2+ T-cell subsets following in vitro infection with Friend murine leukemia virus. Isaak DD; Miceli RM; Lake JP Cell Immunol; 1984 Oct; 88(2):464-74. PubMed ID: 6091923 [TBL] [Abstract][Full Text] [Related]
78. Alteration of cell-surface antigenicity of the mouse plasmacytoma. I. Immunologic characterization of surface antigens masked during successive transplantations. Ono S; Natsu-ume S; Migita S J Natl Cancer Inst; 1975 Sep; 55(3):569-77. PubMed ID: 51090 [TBL] [Abstract][Full Text] [Related]
79. Leukemia-cell rejection due to T-region encoded antigens. Biasi G; Collavo D; Zanovello P; Chieco-Bianchi L Immunogenetics; 1981 Mar; 12(5-6):433-43. PubMed ID: 6971250 [TBL] [Abstract][Full Text] [Related]
80. Selective inhibition by monosaccharides of tumor cell cytotoxicity mediated by mouse macrophages, macrophage-like cell lines, and natural killer cells. Brunda MJ; Wiltrout RH; Holden HT; Varesio L Int J Cancer; 1983 Mar; 31(3):373-9. PubMed ID: 6826257 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]